What is Viatris's market cap?

Viatris (VTRS) has a market capitalization of $19.4B and trades on NASDAQ.

What is Viatris's revenue and profitability?

Viatris generated $14.6B in trailing twelve-month revenue with a net loss of $296.5M, representing a net margin of -2.0%. Gross margin stands at 34.4%, with free cash flow of $1.8B. These figures are based on the Q1 2026 filing.

Who are Viatris's competitors?

Viatris's key competitors include Pfizer Inc., Teva Pharmaceutical Industries Ltd., McKesson Corporation, and others. These companies compete in similar markets and product categories.

Who does Viatris partner with?

Viatris's notable partners include Biocon Biologics, Insud Pharma, S.L., Cooper Consumer Health, and others.

What subsidiaries does Viatris have?

Viatris's subsidiaries include Aculys Pharma, Mylan.

Where is Viatris headquartered?

Viatris is headquartered in United States of America and employs approximately 38,000 people. It has been publicly traded since 1973.

Viatris

VTRS

Market cap

$19.4B+77.4%

Revenue$14.6B+1.6%

Net income-$296.5M+92.2%

Free cash flow$1.8B-5.9%

EPS (diluted)-$0.26+91.8%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q1 2026 report

May 7, 2026

Revenue$3.5BBeat by $160.0M EPS$0.59Beat by $0.07

Read the full report

Next report

Aug 6, 2026 (In 3 weeks)

Revenue estimate$3.7B

EPS estimate$0.62

Financials

Q1 2026

Income statement

See full

Revenue$3.5B+8.1%

Gross profit$1.2B-0.3%

Operating income-$79.7M+97.2%

Net income$176.4M+106%

EPS (diluted)$0.15+106%

Balance sheet

See full

Cash & equivalents$1.8B+139%

Total debt$14.6B+1.0%

Total equity$14.7B-6.3%

Total assets$36.8B-4.3%

Cash flow

See full

Operating cash flow$388.3M-27.5%

CapEx$39.9M-6.3%

Free cash flow$348.4M-29.3%

Valuation & ratios

Valuation

See full

Market cap$19.4B+77.4%

Enterprise value$32.21B+28.1%

P/S1.3×+0.6×

Profitability

See full

Gross margin34.4%-2.5pp

Operating margin1%—

Net margin-2%-1.0pp

FCF margin12.3%-1.0pp

Returns & leverage

See full

Return on equity-2%-0.9pp

Debt / equity1×+0.1×

Current ratio1.6×-0.1×

Segments

By product

See full

Brands$2.3B+10.2%

Generics$1.2B+4.5%

Lipitor$462.0M+19.1%

Norvasc$210.0M+21.9%

Lyrica ®$120.6M+7.1%

By segment

See full

Developed Markets Segment$2.0B+6.7%

Greater China$680.1M+22.4%

Emerging Markets Segment$537.4M+2.7%

Japan, Australia and New Zealand Segment$273.5M-1.3%

Competitors

By market cap

AbbVie$446.54B+33.6%

Merck & Co.$311.17B+53.1%

Pfizer$137.07B-5.0%

McKesson$95.8B+6.7%

Cencora$60.2B—

Viatris$19.4B+77.4%

Vanda Pharmaceuticals$395.7M+35.1%

Cosmos Holdings Inc.$16.4M+32.1%

By revenue growth

Viatris+1.6%

By net margin

Pfizer15.65%+6.3pp

Merck & Co.13.59%-13.7pp

AbbVie5.79%-1.5pp

McKesson1.18%+0.3pp

Cencora0.599%+0.6pp

Viatris-2.04%+24.4pp

Profile

Viatris is a global healthcare company formed through the combination of Mylan and Pfizer's Upjohn business, specializing in a diverse portfolio of medicines including iconic brands, generics, and complex products. The company leverages a massive global supply chain and R&D infrastructure to provide high-quality treatments to approximately one billion patients annually across more than 165 countries. Its core value proposition centers on 'access at scale,' bridging the gap between traditional generic manufacturing and innovative branded pharmaceuticals.

Competitive position

A leading global provider of medicines with a unique hybrid model that combines a massive generic portfolio with iconic established brands and a growing innovative pipeline.

GeographiesNorth America, Europe, China, Japan, Australia, India

Customer segmentsWholesalers, Retailers, Governments, Healthcare Providers

Business modelManufacturing, Research and Development, B2B, Licensing

SuppliersActive Pharmaceutical Ingredient (API) suppliers, Contract Manufacturing Organizations (CMOs), Raw material providers, Clinical trial partners

CustomersPharmaceutical wholesalers, Retail pharmacy chains, Hospitals and health systems, Government health agencies, Insurance companies

CountryUnited States of America

Listed1973

Employees38.0K

CEOScott Andrew Smith

SectorHealthcare

IndustryDrug Manufacturers - Specialty & Generic

Websiteviatris.com

FilingsSEC EDGAR

Ask your AI about Viatris.

Connect your AI assistant and dig into the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Viatris's market cap?: Viatris (VTRS) has a market capitalization of $19.4B and trades on NASDAQ.
What is Viatris's revenue and profitability?: Viatris generated $14.6B in trailing twelve-month revenue with a net loss of $296.5M, representing a net margin of -2.0%. Gross margin stands at 34.4%, with free cash flow of $1.8B. These figures are based on the Q1 2026 filing.
Who are Viatris's competitors?: Viatris's key competitors include Pfizer Inc., Teva Pharmaceutical Industries Ltd., McKesson Corporation, and others. These companies compete in similar markets and product categories.
Who does Viatris partner with?: Viatris's notable partners include Biocon Biologics, Insud Pharma, S.L., Cooper Consumer Health, and others.
What subsidiaries does Viatris have?: Viatris's subsidiaries include Aculys Pharma, Mylan.
Where is Viatris headquartered?: Viatris is headquartered in United States of America and employs approximately 38,000 people. It has been publicly traded since 1973.